Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Summary

This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Timeline

Start

2022-10-03

Primary completion

2026-08-20

Completion

2026-08-20

Drugs

Indications